Mark Plavsic - 15 Mar 2024 Form 3 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Technology Officer
Signature
/s/ Julie Feder, Attorney-in-fact
Issuer symbol
AURA
Transactions as of
15 Mar 2024
Net transactions value
$0
Form type
3
Filing time
25 Mar 2024, 16:01:18 UTC
Previous filing
11 Jan 2023
Next filing
16 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AURA Common Stock 128,515 15 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AURA Stock Option (Right to Buy) 15 Mar 2024 Common Stock 138,000 $8.30 Direct F1
holding AURA Stock Option (Right to Buy) 15 Mar 2024 Common Stock 41,485 $7.77 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest as follows: 25% of the shares vest on September 25, 2024 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
F2 The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney